Denosumab-related osteonecrosis of the jaw

a report of 2 cases and review of the literature

Hardeep K. Chehal, Nikolaos G. Nikitakis, Mohammed N. Islam, Jason H. Goodchild, Lorenzo Mordini, Indraneel Bhattacharyya

Research output: Contribution to journalArticle

Abstract

Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.

Original languageEnglish (US)
Pages (from-to)42-46
Number of pages5
JournalGeneral dentistry
Volume67
Issue number1
StatePublished - Jan 1 2019

Fingerprint

Osteonecrosis
Jaw
Bone Density Conservation Agents
Diphosphonates
Osteoclasts
Bone Density
Osteoporosis
Denosumab
Neoplasm Metastasis
Bone and Bones
Survival
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Dentistry(all)

Cite this

Chehal, H. K., Nikitakis, N. G., Islam, M. N., Goodchild, J. H., Mordini, L., & Bhattacharyya, I. (2019). Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature. General dentistry, 67(1), 42-46.

Denosumab-related osteonecrosis of the jaw : a report of 2 cases and review of the literature. / Chehal, Hardeep K.; Nikitakis, Nikolaos G.; Islam, Mohammed N.; Goodchild, Jason H.; Mordini, Lorenzo; Bhattacharyya, Indraneel.

In: General dentistry, Vol. 67, No. 1, 01.01.2019, p. 42-46.

Research output: Contribution to journalArticle

Chehal, HK, Nikitakis, NG, Islam, MN, Goodchild, JH, Mordini, L & Bhattacharyya, I 2019, 'Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature', General dentistry, vol. 67, no. 1, pp. 42-46.
Chehal HK, Nikitakis NG, Islam MN, Goodchild JH, Mordini L, Bhattacharyya I. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature. General dentistry. 2019 Jan 1;67(1):42-46.
Chehal, Hardeep K. ; Nikitakis, Nikolaos G. ; Islam, Mohammed N. ; Goodchild, Jason H. ; Mordini, Lorenzo ; Bhattacharyya, Indraneel. / Denosumab-related osteonecrosis of the jaw : a report of 2 cases and review of the literature. In: General dentistry. 2019 ; Vol. 67, No. 1. pp. 42-46.
@article{1d94c254f38d4b61bb968e1985a74ed2,
title = "Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature",
abstract = "Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.",
author = "Chehal, {Hardeep K.} and Nikitakis, {Nikolaos G.} and Islam, {Mohammed N.} and Goodchild, {Jason H.} and Lorenzo Mordini and Indraneel Bhattacharyya",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "67",
pages = "42--46",
journal = "General Dentistry",
issn = "0363-6771",
publisher = "Academy of General Dentistry",
number = "1",

}

TY - JOUR

T1 - Denosumab-related osteonecrosis of the jaw

T2 - a report of 2 cases and review of the literature

AU - Chehal, Hardeep K.

AU - Nikitakis, Nikolaos G.

AU - Islam, Mohammed N.

AU - Goodchild, Jason H.

AU - Mordini, Lorenzo

AU - Bhattacharyya, Indraneel

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.

AB - Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85060032344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060032344&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 42

EP - 46

JO - General Dentistry

JF - General Dentistry

SN - 0363-6771

IS - 1

ER -